STOCKIN VITRO & IN VIVO DIAGNOSTIC SUBSTANCESUpdated 2026-08-16
Here’s whether Intellia Therapeutics, Inc (NTLA) is worth buying in 2026 —
based on weekly-updated price trend, RSI momentum, and return vs.
the S&P 500. Our current read: Bearish.
🔴
Bearish
Concerns: trading below the 200-day MA (long-term downtrend); below the 50-day MA (medium-term momentum negative); 50-day MA is falling (-2.16% over 10 days); 3-month momentum negative (-12.9%). Currently 57.8% off its 52-week high. Score: -5/7.
NTLA is trading below its 200-day MA ($12.43) — a key warning sign the longer-term trend is under pressure. An RSI of 67.9 sits in the neutral zone — momentum is neither stretched nor exhausted. The 1-year return of +9.3% compares to +20.4% for SPY (trailed the market by 11.1%). The current 57.8% drawdown from the 52-week high reflects elevated risk for momentum-based strategies.
$10,000 invested 1 year ago→ $10,927 today
vs. S&P 500 (SPY) — same period trailed market by 11.1%
1-Year Price Chart
Daily candles
MA-50MA-200UpDown
Signal Check
✗Above 200-day MA ($12.43)
✗Above 50-day MA ($13.38)
✓RSI(14) neutral zone (30–70) — currently 67.9
✓Positive return (+9.3%)
!Within 10% of period high (−57.8%)
Period Range $11.91
$7.95$28.25
RSI (14) 67.9
0 · OversoldOverbought · 100
Key Metrics
Price$11.91
Period Return+9.3%
Period High$28.25
Period Low$7.95
Drawdown−57.8%
MA-50$13.38
MA-200$12.43
RSI (14)67.9
Avg Volume (30d)4.0M
vs. SPYtrailed by 11.1%
Return Rank#589 of 1252
Trend Signals
Price is below the 200-day moving average ($12.43)